1171897-14-5

Basic information

• Product Name: N-(5-bromopyridin-3-yl)propionamide
• Synonyms: N-(5-bromopyridin-3-yl)propionamide
• CAS NO: 1171897-14-5
• Molecular Formula: C8H9BrN2O
• Molecular Weight: 229.07386
• Mol File: 1171897-14-5.mol
• Article Data: 33

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-(5-bromopyridin-3-yl)propionamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-bromopyridin-3-yl)propionamide(1171897-14-5)
• EPA Substance Registry System: N-(5-bromopyridin-3-yl)propionamide(1171897-14-5)

Safety Data

• Hazardous Substances Data: 1171897-14-5(Hazardous Substances Data)

Usage

General Description

N-(5-bromopyridin-3-yl)propionamide is a chemical compound consisting of a pyridine ring with a bromine atom attached at the 5th position and a propionamide functional group. It is commonly used in organic synthesis and medicinal chemistry as a building block or intermediate for the synthesis of various pharmaceuticals or bioactive compounds. N-(5-bromopyridin-3-yl)propionamide may exhibit properties that are useful for academic research or drug development due to its structural features and potential biological activity. Additionally, it may also be used in the production of agrochemicals, dyes, and other fine chemicals. Overall, N-(5-bromopyridin-3-yl)propionamide has applications in various chemical and pharmaceutical industries and is an important intermediate for the synthesis of diverse organic molecules.

Upstream product

• 13535-01-8 3-amino-5-bromopyridine 
• 802294-64-0 propionic acid 

Relevant articles and documents

3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.